Claims for Patent: 7,612,252

Summary for Patent: 7,612,252

Title:	Homeotic genes and proteins, uses thereof
Abstract:	The homeotic gene AGL42 in Arabidopsis has been cloned and characterized and is presented herein, both alone and in association with expression control sequences and in vectors which may be used e.g. for transgenic expression. The gene exhibits the role of controlling meristem maintenance. A labeled construct is shown to serve as a marker for identity of the quiescent cells within the meristem. Both the DNA and protein are disclosed.
Inventor(s):	Benfey; Philip (Chapel Hill, NC), Nawy; Tal (Durham, NC)
Assignee:
Application Number:	10/482,605
Patent Claims:	1. The construct pAGL42::GFP having ATCC Accession No. PTA-9607. 2. A nucleic acid construct comprising AGL42 sequence fused to a marker, wherein the AGL42 sequence confers expression of the marker in the central cells or quiescent center of a plant, wherein the AGL42 sequence is comprised of upstream promoter sequence, first exon sequence, first intron sequence and second exon sequence of AGL42, and wherein the first exon sequence is as set out in SEQ ID NO: 3 and the second exon sequence is as set out in SEQ ID NO: 4 and wherein the construct is pAGL42::GFP having ATCC Accession No. PTA-9607. 3. The construct of claim 2 wherein the marker is green fluorescent protein (GFP). 4. A method of identifying and monitoring the central cells or quiescent center in a plant comprising inserting into the genome of said plant or expressing in said plant the construct pAGL42::GFP having ATCC Accession No. PTA-9607.

Details for Patent 7,612,252

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2021-06-25
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2021-06-25
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2021-06-25